# Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression

> **NCT00883493** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 421 (actual)

## Conditions studied

- Acute Bipolar Depression

## Interventions

- **DRUG:** Quetiapine fumarate XR
- **DRUG:** Lithium carbonate

## Key facts

- **NCT ID:** NCT00883493
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2012-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883493, "Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00883493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*